ZA972554B - ErbB3 antibodies - Google Patents

ErbB3 antibodies

Info

Publication number
ZA972554B
ZA972554B ZA972554A ZA972554A ZA972554B ZA 972554 B ZA972554 B ZA 972554B ZA 972554 A ZA972554 A ZA 972554A ZA 972554 A ZA972554 A ZA 972554A ZA 972554 B ZA972554 B ZA 972554B
Authority
ZA
South Africa
Prior art keywords
erbb3
erbb2
heregulin
ability
cell
Prior art date
Application number
ZA972554A
Other languages
English (en)
Inventor
Robert Akita
Mark Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA972554(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA972554B publication Critical patent/ZA972554B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
ZA972554A 1996-03-27 1997-03-25 ErbB3 antibodies ZA972554B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62403696A 1996-03-27 1996-03-27

Publications (1)

Publication Number Publication Date
ZA972554B true ZA972554B (en) 1998-09-25

Family

ID=24500380

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA972554A ZA972554B (en) 1996-03-27 1997-03-25 ErbB3 antibodies

Country Status (15)

Country Link
EP (2) EP0896586B2 (da)
JP (1) JP3925943B2 (da)
CN (1) CN1214044C (da)
AT (1) ATE342283T1 (da)
AU (1) AU727082B2 (da)
BR (1) BR9708343A (da)
CA (1) CA2246429C (da)
DE (1) DE69736806T3 (da)
DK (1) DK0896586T4 (da)
ES (1) ES2274537T5 (da)
IL (2) IL126303A0 (da)
NZ (1) NZ331360A (da)
PT (1) PT896586E (da)
WO (1) WO1997035885A1 (da)
ZA (1) ZA972554B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2008200654B2 (en) * 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
EP1495123B1 (en) 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Erbb3 based methods and compositions for treating neoplasms
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EA022884B1 (ru) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
DK3351558T3 (da) 2009-11-13 2020-06-02 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
US8859737B2 (en) 2009-12-22 2014-10-14 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
PT2544680E (pt) 2010-03-11 2015-05-06 Merrimack Pharmaceuticals Inc Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
CA2803900A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2616961T3 (es) * 2010-11-01 2017-06-14 Symphogen A/S Composición de anticuerpos pan-HER
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
EP2797957B1 (en) * 2011-11-23 2019-06-19 MedImmune, LLC Binding molecules specific for her3 and uses thereof
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
EA201500503A1 (ru) * 2012-11-08 2015-10-30 Ф.Хоффманн-Ля Рош Аг Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
CN106459207B (zh) 2014-05-14 2020-07-10 豪夫迈·罗氏有限公司 结合HER3β-发夹的抗HER3抗体
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2022078490A1 (zh) * 2020-10-15 2022-04-21 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
AU4025193A (en) * 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
EP1728802A2 (en) 2006-12-06
CA2246429C (en) 2007-07-24
DK0896586T3 (da) 2007-02-19
JP3925943B2 (ja) 2007-06-06
CA2246429A1 (en) 1997-10-02
EP0896586B2 (en) 2015-05-20
DE69736806T3 (de) 2015-10-08
EP0896586B1 (en) 2006-10-11
CN1214044C (zh) 2005-08-10
DK0896586T4 (da) 2015-08-24
IL126303A (en) 2002-05-23
ES2274537T5 (es) 2015-09-14
PT896586E (pt) 2007-01-31
BR9708343A (pt) 1999-08-03
JP2000508526A (ja) 2000-07-11
DE69736806D1 (de) 2006-11-23
ES2274537T3 (es) 2007-05-16
EP1728802A3 (en) 2006-12-13
ATE342283T1 (de) 2006-11-15
IL126303A0 (en) 1999-05-09
CN1214695A (zh) 1999-04-21
AU727082B2 (en) 2000-11-30
DE69736806T2 (de) 2007-08-09
NZ331360A (en) 2000-03-27
AU2071197A (en) 1997-10-17
EP0896586A1 (en) 1999-02-17
WO1997035885A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
ZA972554B (en) ErbB3 antibodies
EP1071460A4 (en) INTERNALIZING ERB2 ANTIBODIES
IL223048A (en) Variant peptides linking fcrn with increased affinity and method for their production
DE69740038D1 (da)
GR3024489T3 (da)
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
EP0930365A3 (en) Binding domains in serrate protein
IL132560A0 (en) A method for making multispecific antibodies having heteromultimeric and common components
EP0728215A4 (en) METHOD FOR BINDING MATERIAL TO THE -g (b) AMYLOID PEPTIDE
EP1695986A3 (en) Anti-erb B2 antibodies
IL191077A0 (en) An isolated antibody which binds to the n-terminal domain of gamma-heregulin and methods using it
WO2001004144A3 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
CA2172376A1 (en) Antibodies to cd40
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
WO2000001815A3 (en) Neurotrophic factors
CA2135208A1 (en) Immunoglobulin binding proteins derived from l protein and their uses
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
AU2236795A (en) Afamin: a human serum albumin-like protein
AU5301196A (en) Method for stimulating an immune response
EP1510579A3 (en) Use of heregulin as an epithelial cell growth factor
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
AU3063297A (en) Cellular internalization of pigr stalk and associated ligands
CA2589421A1 (en) Erbb3 antibodies
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
WO1999025734A3 (en) Th2 CELL DEPLETION; COMPOSITIONS; METHODS